{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:12Z","timestamp":1784696772239,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00535-019-01582-w","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T13:40:58Z","timestamp":1556631658000},"page":"860-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Withdrawal of thiopurines in Crohn\u2019s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)"],"prefix":"10.1007","volume":"54","author":[{"name":"DIAMOND2 Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Kunisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Nagahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00535-018-1479-6","volume":"53","author":"HY Shi","year":"2018","unstructured":"Shi HY, Ng SC. The state of the art on treatment of Crohn\u2019s disease. J Gastroenterol. 2018;53:989\u201398.","journal-title":"J Gastroenterol"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","volume":"53","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305\u201353.","journal-title":"J Gastroenterol"},{"key":"1582_CR3","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Magdelaine-Beuzelin C, D\u2019Haens G, et al. Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861\u20138.","journal-title":"Gastroenterology"},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","volume":"146","author":"MT Osterman","year":"2014","unstructured":"Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease. Gastroenterology. 2014;146:941\u20139.","journal-title":"Gastroenterology"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/apt.12076","volume":"36","author":"C Reenaers","year":"2012","unstructured":"Reenaers C, Louis E, Belaiche J, et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn\u2019s disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36:1040\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","volume":"8","author":"U Kopylov","year":"2014","unstructured":"Kopylov U, Al-Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn\u2019s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1632\u201341.","journal-title":"J Crohns Colitis"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","volume":"10","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial. J Crohns Colitis. 2016;10:1259\u201366.","journal-title":"J Crohns Colitis"},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.14318","volume":"46","author":"H Nakase","year":"2017","unstructured":"Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46:873\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"1582_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cgh.2017.10.036","volume":"16","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and pharmacokinetic factors associated with mucosal healing induced by adalimumab in patients with Crohn\u2019s disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). Clin Gastroenterol Hepatol. 2018;16:542\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Beckrel JM, Singleton JW, et al. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1976;70:439\u201344.","journal-title":"Gastroenterology"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3109\/00365521003642559","volume":"45","author":"S Kochi","year":"2010","unstructured":"Kochi S, Matsumoto T, Esaki M, et al. Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel disease during long-term thiopurine administration. Scand J Gastroenterol. 2010;45:608\u201314.","journal-title":"Scand J Gastroenterol"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Heans G, van Asshche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease. The SES-CD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"key":"1582_CR14","doi-asserted-by":"publisher","first-page":"s358","DOI":"10.1016\/S0016-5085(10)61648-4","volume":"138","author":"M Ferrante","year":"2010","unstructured":"Ferrante M, Noman M, Vermeire S. Evolution of endoscopic activity scores under placebo therapy in Crohn\u2019s disease. Gastroenterology. 2010;138:s358.","journal-title":"Gastroenterology"},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-S","volume":"583","author":"L Lennard","year":"1992","unstructured":"Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine. Quantification of red blood cell 6-thioguanine nucleotide, 6-thionosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583:83\u201390.","journal-title":"J Chromatogr"},{"key":"1582_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartends","year":"2007","unstructured":"Bartends GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab. Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1582_CR18","first-page":"CD012540","volume":"5","author":"RK Boyapati","year":"2018","unstructured":"Boyapati RK, Torres J, Palmela C, et al. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn\u2019s disease. Cochrane Database Syst Rev. 2018;5:CD012540.","journal-title":"Cochrane Database Syst Rev"},{"key":"1582_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"JP Terdiman","year":"2013","unstructured":"Terdiman JP, Gruss C, Heidelbaugh JJ, et al. American Gastroenterological Association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease. Gastroenterology. 2013;145:1459\u201363.","journal-title":"Gastroenterology"},{"key":"1582_CR20","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5\u00a0years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409\u201322.","journal-title":"Am J Gastroenterol"},{"key":"1582_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325.","journal-title":"Lancet"},{"key":"1582_CR22","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/ajg.2011.283","volume":"106","author":"LJ Herrinton","year":"2011","unstructured":"Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease. J Gastroenterol. 2014;49(1):100\u20139.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1582_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40(6):620\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00535-017-1416-0","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53:172\u201380.","journal-title":"J Gastroenterol"},{"issue":"9","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53(9):1065\u201378.","journal-title":"J Gastroenterol"},{"key":"1582_CR27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139.","journal-title":"Gut"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01582-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T10:05:12Z","timestamp":1589882712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01582-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01582-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T Hisamatsu: Honoraria: EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Mochida Pharmaceutical Co., Ltd., Nichi-lko Pharmaceutical Co., Ltd. Commercial research funding: EA pharma Co. Ltd., AbbVie GK, Daiichi-Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Mochida Pharmaceutical Co., Ltd., Astellas Pharma Inc., Asahi Kasei Medical Co., Ltd., ZERIA Pharmaceutical Co. Ltd. S. Kato: Honoraria: Mistubishi Tanabe Pharma Corporation, Janssenn Pharma K,K. R. Kunisaki: Honoraria: AbbVie GK, EA pharma Co. Ltd., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Kissei Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Nioppon Kayaku Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., ZERIA Pharmaceutical Co. Ltd. Commercial research funding: AbbVie GK, EA pharma Co. Ltd., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Kissei Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, RPM Co. Ltd, Takeda Pharmaceutical Co. Ltd. M. Matsuura: Honoraria: AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nioppon Kayaku Co. Ltd., Kissei Pharmaceutical Co. Ltd. Commercial research funding: AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., Mochida Pharmaceutical Co., Ltd., Nioppon Kayaku Co. Ltd., JIMRO Co. M. Nagahori: Honoraria: Kissei Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co., Ltd., AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Nioppon Kayaku Co. Ltd., Asahi Kasei Medical Co., Ltd., ZERIA Pharmaceutical Co. Ltd., Astellas Pharma Inc., Nichi-lko Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K. S. Motoya: Honoraria: Eisai Corporation, AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Mochida Pharma Corporation, Janssen Pharmaceutical K.K. M. Esaki: Honoraria: AbbVie, Mitsubishi Tanabe Pharma Corporation. Commercial research funding: EA pharma Co. Ltd., AbbVie GK, Mitsubishi Tanabe Pharma Corporation. N. Fukata: no conflict of interest. S. Inoue: no conflict of interest. T. Sugaya: no conflict of interest. H. SAKURABA: Commercial research funding: Bristol-Myers Squibb, AbbVie GK, MSD Inc., Daiichi-Sankyo Co. Ltd., ZERIA Pharmaceutical Co. Ltd. F. Hirai: Honoraria: EA Pharma CO. Ltd, AbbVie GK, Mitsugishi Tanabe Pharma, Eisai CO.,Ltd. K. Watanabe: Honoraria: EA Pharma Co. Ltd., AbbVie, Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co. Ltd. Commercial research funding: EA Pharma Co. Ltd., AbbVie, Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Astellas Pharma Inc. T. Kanai: Honoraria: EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., Yakult Honsha Co., Ltd., ZERIA Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd. Commercial research funding: Eisai Corporation, JIMRO Co. Ltd., Nippon Kayaku Co. Ltd., Daiichi-Sankyo Co. Ltd., Tsumura & Co., Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., EN Otsuka Pharmaceutical Co. Ltd., Ezaki Glico Co. Ltd., RPM Co. Ltd., Yakult Bio-Science Foundation.M. Naganuma: Honoraria: EA Pharma Co. Ltd. Commercial research funding: EA Pharma Co. Ltd., ZERIA, Mochida Pharmaceutical CO. Ltd. H. Nakase: Honoraria: Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical CO. Ltd., Janssen Pharmaceutical K.K, AbbVie GK. Commercial research funding: Hoya group Pentax Medical. Boehringer Ingelheim GmbH, Daticho-Sankyo Co. Ltd. Y. Suzuki: Honoraria: AbbVie GK, Mitsubishi Tanabe Pharma Corporation, ZERIA Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., EA pharma Co. Ltd., Janssen Pharmaceutical K.K. Commercial research funding: AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., JIMRO Co. Ltd., Mochida Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., KISSEI. M. Watanabe: Honoraria: Mitsubishi Tanabe Pharma Corp., Eisai Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Ltd., AbbVie GK, Takeda Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., ZERIA Pharmaceutical Co. Ltd., Asahi Kasei Medical Co. Ltd., EA Pharma Co. Ltd., Astellas Pharma Inc., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical Co. Ltd., Gilead Sciences, Inc., Celgene Corp., Kissei Pharmaceutical Co. Ltd. Commercial research funding: Asahi Kasei Medical Co. Ltd., AbbVie GK, EA Pharma Co. Ltd., Eisai Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., Otsuka Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., ZERIA Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Mochida Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Astellas Pharma Inc., MSD K.K., Dainippon Sumitomo Dainippon Pharma Co. Ltd., Bristol-Myers, K.K, Chugai Pharmaceutical Co. Ltd., Gilead Sciences Inc., Pfizer Inc., Miyarisan Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd. T. HIBI: Honoraria: Mitsubishi Tanabe Pharma CO., AbbVie GK, EA Pharma Co., Ltd. M. Nojima: no conflict of interest. T. Matsumoto: Honoraria: Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co. Ltd., Janssen Pharmaceutical K.K. Commercial research funding: Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., Nippon Kayaku Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}